Rankings
▼
Calendar
EOLS Q3 2025 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena
EOLS
Evolus, Inc.
$353M
Q3 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$69M
+12.9% YoY
Gross Profit
$46M
66.5% margin
Operating Income
-$12M
-16.7% margin
Net Income
-$16M
-22.8% margin
EPS (Diluted)
$-0.24
QoQ Revenue Growth
-0.6%
Cash Flow
Operating Cash Flow
-$15M
Free Cash Flow
-$17M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$219M
Total Liabilities
$248M
Stockholders' Equity
-$29M
Cash & Equivalents
$44M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$69M
$61M
+12.9%
Gross Profit
$46M
$43M
+7.0%
Operating Income
-$12M
-$15M
+25.7%
Net Income
-$16M
-$19M
+17.9%
Revenue Segments
Product
$69M
100%
← FY 2025
All Quarters
Q4 2025 →